Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4296.

https://doi.org/10.1182/blood-2023-187044

Published: 2023

Journal Articles

Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study

Amir T. Fathi, Theodore P Braun, Alexander Joseph Ambinder, Gautam Borthakur, Robert L. Redner, Mabel Arevalo, Sonia Gutierrez, Ana Limon, Douglas V. Faller

Blood (2023) 142 (Supplement 1): 5974.

https://doi.org/10.1182/blood-2023-189291

Published: 2023

Journal Articles

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

Blood (2023) 142 (Supplement 1): 4332.

https://doi.org/10.1182/blood-2023-181886

Published: 2023

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2023) 142 (Supplement 1): 1535.

https://doi.org/10.1182/blood-2023-187383

Published: 2023

Journal Articles

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Blood (2023) 142 (Supplement 1): 5933.

https://doi.org/10.1182/blood-2023-179609

Published: 2023

Journal Articles

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2022) 140 (Supplement 1): 6200–6203.

https://doi.org/10.1182/blood-2022-167316

Published: 2022

Journal Articles

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 9070–9073.

https://doi.org/10.1182/blood-2022-166715

Published: 2022

Journal Articles

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Konstantinos Lontos, Robert L. Redner, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic J. Farah, Annie Im, Kathleen Dorritie, Alison R. Sehgal, James M. Rossetti, Daniel Normolle, Michael M. Boyiadzis

Blood (2022) 140 (Supplement 1): 6145–6146.

https://doi.org/10.1182/blood-2022-156468

Published: 2022

Journal Articles

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 875.

https://doi.org/10.1182/blood-2021-149115

Published: 2021

Journal Articles

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1277.

https://doi.org/10.1182/blood-2021-148207

Published: 2021

Journal Articles

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Blood (2021) 138 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2021-151234

Published: 2021

Journal Articles

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Anastasia Tsagianni, MD, Konstantinos Lontos, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic J. Farah, MD, Robert L. Redner, MD, Annie Im, MD, Kathleen A. Dorritie, MD, Alison R. Sehgal, MD, James M. Rossetti, DO, Melissa Saul, MS, William Gooding, MS, Michael Boyiadzis, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138561

Published: 2020

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Asha Ricciuti, MD, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD PhD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, James M. Rossetti, DO, Yongli Shuai, PhD, Daniel Normolle, PhD, Rahim Remtulla, MD, Shawn Tahata, MD, Michael Boyiadzis, MD, Annie Im, MD

Blood (2018) 132 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2018-99-113935

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Blood (2017) 130 (Supplement 1): 2633.

https://doi.org/10.1182/blood.V130.Suppl_1.2633.2633

Published: 2017

Journal Articles

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Michael Boyiadzis, MD MHSc, Mounzer Agha, MD, Robert L Redner, MD, Alison Sehgal, MD, Annie Im, MD, Jing-Zhou Hou, Rafic Farah, MD, Kathleen A. Dorritie, MD, Anastasios Raptis, MD PhD, Seah H. Lim, MDPhDFRCP,FRCPath,MBBS, Hans Klingemann, MD PhD, Hong Wang, PhD, Natalia Lapteva, PhD, Mei Zhuyong, MD, Lisa H Butterfield, PhD, Cliona M. Rooney, PhD, Theresa L Whiteside, PhD

Blood (2016) 128 (22): 1649.

https://doi.org/10.1182/blood.V128.22.1649.1649

Published: 2016

Journal Articles

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Suzanne Lentzsch, Nicolas Villanueva, MD, James Nguyen, BS, Heather Landau, MD, Nikoletta Lendvai, MDPhD, Susanna Miao, BA, Jordan M. Schecter, MD, Mariamne Reyna, BS, Markus Y Mapara, MD PhD, Robert L. Redner, MD, David J Chung, MDPhD, Alexander M. Lesokhin, MD, Tarun Kewalramani, MD, Sergio Giralt, MD, Raymond L. Comenzo, MD, Ola Landgren, MD PhD, Hani Hassoun, MD

Blood (2015) 126 (23): 1975.

https://doi.org/10.1182/blood.V126.23.1975.1975

Published: 2015

Journal Articles

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

Annie Im, MD, Jing-Zhou Hou, MD PhD, Anastasios Raptis, MD, Mounzer Agha, MD, Rafic Farah, MD, Robert L. Redner, MD, Alison R. Sehgal, MD, Kathleen A. Dorritie, MD, Ann Welsh, RN, Daniel E. Johnson, PhD, Daniel Normolle, PhD, Michael Boyiadzis, MD

Blood (2014) 124 (21): 2265.

https://doi.org/10.1182/blood.V124.21.2265.2265

Published: 2014

Journal Articles

NPM-RAR Binding To Tradd Selectively Blocks TNF-Induced Apoptosis While Allowing TNF Activation Of JNK

Robert L. Redner, MD, Anuja Chattopadhyay, Brian L. Hood, PhD, Thomas P. Conrads, PhD

Blood (2013) 122 (21): 4904.

https://doi.org/10.1182/blood.V122.21.4904.4904

Published: 2013

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Patients with Refractory Acute Myeloid Leukemia

Annie Im, MD, Navkiranjit Gill, DO, Diana Cunningham, MS, Mounzer Agha, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD, PhD, Robert L. Redner, MD, Julie Phillips, MSN, CRNP, BC, Michael Boyiadzis, MD, MHSc

Blood (2012) 120 (21): 4531.

https://doi.org/10.1182/blood.V120.21.4531.4531

Published: 2012

NARROW

Genomic Characterization of Newly Diagnosed Acute Myeloid Leukemia in Patients Age 60 Years and Older; A Report from the Beat AML Master Trial

Iadademstat and Gilteritinib for the Treatment of FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia: The Frida Study

Influence of Pre-Treatment Features and Therapy Choice By Physicians on Overall Survival in Older Adults with Acute Myeloid Leukemia: A Report from the Beat AML Master Trial

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Beat AML S8 Group 2: Gilteritinib (GILT) in Combination with Decitabine (DEC) and Venetoclax (VEN) in Untreated FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Age ≥60 with High and Low Variant Allele Frequency (VAF)

Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1 -Mutated and FLT3 -ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1 -Mutated/ FLT3 -Wild Type AML or KMT2A -Rearranged Acute Myeloid Leukemia (AML)

Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1 st Induction Regimen

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Pretreatment Next-Generation Sequencing Is Associated with Response to Induction Chemotherapy in Patients Newly Diagnosed with Acute Myeloid Leukemia

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Higher Number of Cycles of Cytarabine Consolidation Improves Outcomes in Elderly AML Patients

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia

Continuous Treatment with Lenalidomide Plus Low-Dose Dexamethasone (Ld) Versus Ld Induction Followed By Autologous Stem Cell Transplant (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Pooled Analysis of Two Randomized Clinical Trials

Epigenetic Priming Using Decitabine Followed By Cytarabine As an Induction Regimen in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

NPM-RAR Binding To Tradd Selectively Blocks TNF-Induced Apoptosis While Allowing TNF Activation Of JNK

Outcomes of Hematopoietic Cell Transplantation in Patients with Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only